@article{40e17411a6594339880f0d39818bee88,
title = "Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients",
abstract = "Purpose: The aromatase inhibitors (AI) exemestane (EXE), letrozole (LET), and anastrozole suppress estrogen biosynthesis, and are effective treatments for estrogen receptor (ER)-positive breast cancer. Prior work suggests that anastrozole blood concentrations are associated with the magnitude of estrogen suppression. The objective of this study was to determine whether the magnitude of estrogen suppression, as determined by plasma estradiol (E2) concentrations, in EXE or LET treated patients is associated with plasma AI concentrations. Methods: Five hundred post-menopausal women with ER-positive breast cancer were enrolled in the prospective Exemestane and Letrozole Pharmacogenetic (ELPh) Study conducted by the COnsortium on BReast cancer phArmacogomics (COBRA) and randomly assigned to either drug. Estrogen concentrations were measured at baseline and after 3 months of AI treatment and drug concentrations were measured after 1 or 3 months. EXE or LET concentrations were compared with 3-month E2 concentration or the change from baseline to 3 months using several complementary statistical procedures. Results: Four-hundred patients with on-treatment E2 and AI concentrations were evaluable (EXE n = 200, LET n = 200). Thirty (7.6%) patients (EXE n = 13, LET n = 17) had 3-month E2 concentrations above the lower limit of quantification (LLOQ) (median: 4.75; range: 1.42–63.8 pg/mL). EXE and LET concentrations were not associated with on-treatment E2 concentrations or changes in E2 concentrations from baseline (all p > 0.05). Conclusions: Steady-state plasma AI concentrations do not explain variability in E2 suppression in post-menopausal women receiving EXE or LET therapy, in contrast with prior evidence in anastrozole treated patients.",
keywords = "Aromatase inhibitor, Breast cancer, Estradiol, Exemestane, Letrozole, Pharmacokinetics",
author = "Hertz, {Daniel L.} and Speth, {Kelly A.} and Kidwell, {Kelley M.} and Gersch, {Christina L.} and Zeruesenay Desta and Storniolo, {Anna Maria} and Vered Stearns and Skaar, {Todd C.} and Hayes, {Daniel F.} and Henry, {N. Lynn} and Rae, {James M.}",
note = "Funding Information: Acknowledgements This research was supported by Pharmacogenetics Research Network Grant No. U-01 GM61373 (D.A.F.) and Clinical Pharmacology Training Grant No. 5T32-GM08425 (D.A.F.) from the National Institute of General Medical Sciences, National Institutes of Health (NIH), from Grants No. M01-RR000042 (University of Michigan), M01-RR00750 (Indiana University), and M01-RR00052 (Johns Hopkins University) from the National Center for Research Resources (NCRR), a component of the NIH, the Breast Cancer Research Foundation (BCRF) (N003173 to JMR and DFH), the National Cancer Institute (5T32CA083654-12, PI Jeremy Taylor), the National Institute of General Medical Sciences (GM099143 to J.M.R.) and the National Institutes of Health through the University of Michigan{\textquoteright}s Cancer Center Support Grant (P30 CA046592) by the use of the following Cancer Center Core: University of Michigan DNA Sequencing Core. In addition, these studies were supported by grants from Pfizer (D.F.H.), Novartis Pharma AG (D.F.H.), the Fashion Footwear Association of New York/QVC Presents Shoes on Sale (D.F.H.). Drugs were supplied by Novartis and Pfizer. We also wish to posthumously recognize David Flockhart, MD, PhD, who cochaired the COnsortium on BReast cancer phArmacogomics (COBRA) and passed during preparation of this manuscript. Funding Information: This research was supported by Pharmacogenetics Research Network Grant No. U-01 GM61373 (D.A.F.) and Clinical Pharmacology Training Grant No. 5T32-GM08425 (D.A.F.) from the National Institute of General Medical Sciences, National Institutes of Health (NIH), from Grants No. M01-RR000042 (University of Michigan), M01-RR00750 (Indiana University), and M01-RR00052 (Johns Hopkins University) from the National Center for Research Resources (NCRR), a component of the NIH, the Breast Cancer Research Foundation (BCRF) (N003173 to JMR and DFH), the National Cancer Institute (5T32CA083654-12, PI Jeremy Taylor), the National Institute of General Medical Sciences (GM099143 to J.M.R.) and the National Institutes of Health through the University of Michigan?s Cancer Center Support Grant (P30 CA046592) by the use of the following Cancer Center Core: University of Michigan DNA Sequencing Core. In addition, these studies were supported by grants from Pfizer (D.F.H.), Novartis Pharma AG (D.F.H.), the Fashion Footwear Association of New York/QVC Presents Shoes on Sale (D.F.H.). Drugs were supplied by Novartis and Pfizer. We also wish to posthumously recognize David Flockhart, MD, PhD, who co-chaired the COnsortium on BReast cancer phArmacogomics (COBRA) and passed during preparation of this manuscript. This work was submitted in preliminary form to 2017 American Society for Clinical Oncology Annual Meeting. Publisher Copyright: {\textcopyright} 2017, Springer Science+Business Media, LLC.",
year = "2017",
month = oct,
day = "1",
doi = "10.1007/s10549-017-4346-x",
language = "English (US)",
volume = "165",
pages = "659--668",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",
}